• MetLife (NYSE:MET) shares fell 7.4% after the shares were downgraded by Raymond James Financial on valuation concerns

• BP (NYSE:BP) announced a "giant" new oil discovery in the Gulf of Mexico, named "Tiber," one of the deepest wells ever drilled

• Acadia Pharmaceuticals (NASDAQ:ACAD) reported disappointing Phase III trail results for its primavanserin drug in treatment of Parkinson's disease psychosis

• Joy Global (NASDAQ:JOYC) announced fiscal third quarter earnings of $1.21 per share, beating estimates of 95 cents a share, on revenues of $956 million, up from projections of $902.4 million. The firm said it sees 2009 revenues to equal its prior $3.5 billion to $3.6 billion guidance, and raised its earnings guidance to $4.00 to $4.20 per share, from its view of $3.80 to $4.00 per share

• Textron (NYSE:TXT) was upgraded by Goldman Sachs (NYSE:GS) to "buy" from "neutral."  Goldman also added the firm to its conviction buy list with a

...

Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth quarter of this year, has been approved by both company boards. Additionally, Neurogen shareholders, representing approximately 33% of outstanding shares, have already given their nod in favor of the deal. The terms of the deal require Ligand to issue about 4 million new shares to Neurogen shareholders, which is equivalent to a purchase price of 16 cents per common share of Neurogen. Neurogen stockholders would hold 3% of the combined company. The transaction will give Ligand shareholders access to Neurogen's partnership with Merck & Co., Inc. (MRK). Ligand will also have access to additional pipeline assets and ...

Markets closing with PWRM trading over 16 MILLION Shares Last: 0.034 Open: 0.018 Change: 100.00%

Keep an eye out for PWRM.OB

PWRM.OB Power Medical Products Inc. Power3 Medical Products, Inc., a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimer?s disease, and Parkinson?s disease. Web Site: http://www.Power3Medical.com

Recent News: Power3 Medical Products, Inc. Files for 3 Patents On Blood Test for Diagnosis of Early Stage Breast Cancer

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations.

Stock-PR Monday August 24, 2009 Watch List!

Arabian American Development Company (ARSD) Arabian American Development Company, through its subsidiaries, engages in the manufacture and sale of various specialty petrochemical products, as well as the development of mineral properties in Saudi Arabia and the United States. Web Site: http://www.arabianamericandev.com

ConocoPhillips (COP) ConocoPhillips operates as an integrated energy company worldwide. The company operates through six segments: Exploration and Production (E&P), Midstream, Refining and Marketing (R&M), LUKOIL Investment, Chemicals, and Emerging Businesses Web Site: http://www.conocophillips.com

Recent News: Oil company ConocoPhillips spent nearly $3.3 million in the second quarter lobbying Congress on proposed climate-change and health care reform legislation, among other issues, according to a recent disclosure report. That was more than double what it spent in the year-ago period.

Power 3 Medical Products Inc. (PWRM.OB) Power3 Medical Products, Inc., a development stage company, engages in commercializing its intellectual properties in the area of diagnosis

...

Las Vegas - CRWENewswire.com is pleased to announce a stock highlight on Power3 Medical Products, Inc. (OTCBB:PWRM), Xerox Corporation (NYSE: XRX, Cavitation Technologies, Inc. CVAT.OB,

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.power3medical.com), announced today that the Company has filed a patent for Diagnosis of Early Stage Parkinsons Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.

Xerox Corporation (NYSE: XRX) digital production color devices account for more than 50 percent of the total worldwide page volume1 – and now print providers have another option for their digital printing needs with the launch of the Xerox DocuColor® 7002/8002 Digital Presses.

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinsons disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinsons, in validation, utility, but that the importance of the

...

Las Vegas - CRWENewswire.com is pleased to announce a stock highlight on Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the Company has filed a patent for Diagnosis of Early Stage Parkinsons Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.

Xerox Corporation (NYSE: XRX) digital production color devices account for more than 50 percent of the total worldwide page volume1 - and now print providers have another option for their digital printing needs with the launch of the Xerox DocuColor® 7002/8002 Digital Presses.

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinsons disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinsons, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test.

...

Las Vegas - CRWENewswire.com is pleased to announce a stock highlight on Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the Company has filed a patent for Diagnosis of Early Stage Parkinsons Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinsons disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinsons, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test. This work was done in conjunction with Transgenomic, Inc. license/collaboration agreement. The patent provides coverage of biomarkers and the computation/statistical methods used to discriminate the disease vs. the normal controls.

“Power3 Medical is continuing the portfolio of it intellectual property in Neurodegenerative diagnosis.

...

On July 1, 2009, CombinatoRx (CRXX) agreed to merge with Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in Canada.As per the terms of the all-stock deal, CombinatoRx will issue approximately 36 million new shares to Neuromed shareholders.  Initially, each party will own about 50% of the merged entity. The ownership stake will then be adjusted on the basis of the approvability status of Exalgo, a product currently under U.S. FDA review.Exalgo is a once-daily extended release formulation of hydromorphone, which has been developed for the treatment of chronic to severe pain. Neuromed recently sold U.S. rights to Exalgo to Mallinckrodt, a subsidiary of Covidien (COV).   The U.S. opioid market represents a significant commercial opportunity. Although several opioid products (including generics) are available, the market is large and growing. Currently, no long-acting form of hydromorphone is available ...

We are initiating coverage of DepoMed (DEPO) with a Buy rating and $5 price target. We are excited about the potential for Serada, and enhanced formulation of gabapentin that utilizes the company's proprietary AcuForm technology, for the treatment of hot flashes / vasomotor symptoms (VMS) in menopausal women.Serada is currently in two phase III trials with data expected in the fourth quarter of 2009. Gabapentin is a molecule that has been well studied in hot flashes / VMS, and meta analysis shows it is the superior non-HRT efficacy option out there. Unfortunately, the dosing requirements and side-effect profile of the drug dramatically limits prescriptions in this market.With Serada, DepoMed is a significant opportunity in our view. We see the drug as a potential $500 million or more opportunity.DepoMed is also developing its AcuForm-enhanced gabapentin molecule for the treatment of neuropathic ...

For Immediate Release

Chicago, IL - March 31, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Ness Technologies (NSTC), American Capital Agency Corp (AGNC), Biogen Idec (BIIB), Sohu.com Inc (SOHU) and Cornerstone Therapeutics Inc (CRTX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Monday's Analyst Blog:

Ness Tech with More Downside

Ness Technologies (NSTC) is a small player in the IT services market. The company posted mixed 4Q08 results, with revenue below expectation but in line EPS.

The company's Application Development and Software Product Engineering segment performed very well in 4Q08. However,

...